Vollmer-Conna, U, Hickie, I, Hadzi-Pavlovic, D et al. · The American journal of medicine · 1997 · DOI
This study tested whether intravenous immunoglobulin (IVIg)—a blood product containing antibodies—could help treat ME/CFS. Ninety-nine patients received either IVIg at different doses or a placebo monthly for 3 months. The researchers found that IVIg at any dose did not improve symptoms, quality of life, or daily functioning compared to placebo. Side effects were common in both groups, suggesting IVIg is not an effective treatment for ME/CFS.
This high-quality trial provides evidence that IVIg, despite early anecdotal reports, does not benefit ME/CFS patients and should not be recommended as standard therapy. The rigorous design and negative result help redirect limited research resources and prevent patients from pursuing ineffective treatments with potential risks and high costs. It underscores that mechanistic understanding of ME/CFS pathophysiology is essential before targeted interventions can be developed.
This study does not prove that immune dysfunction is absent in ME/CFS, only that non-specific immunoglobulin replacement is ineffective. It does not identify which ME/CFS patients, if any, might respond to other immunologic therapies. The study's 3-month treatment window does not rule out potential benefit from longer-term or higher-dose IVIg protocols, though such extension would require independent evidence.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →